GSK To Start Clinical Tests For Ebola Vaccine

News outlets report on GlaxoSmithKline’s announcement that it will begin to clinically test an Ebola vaccine.

The Hill: Glaxo to start clinical trials for Ebola vaccine
“British drugmaker GlaxoSmithKline will start clinically testing an Ebola vaccine as international health workers struggle to contain an outbreak of the deadly disease. Glaxo will partner with the National Institutes of Health (NIH) to start a Phase I trial, giving the vaccine to a limited number of patients to test its effectiveness, in the next few months…” (Al-Faruque, 8/11).

Reuters: Clinical trial to start soon on GSK Ebola vaccine
“A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists…” (Hirschler, 8/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.